No Image 01Jun

by

Profiles of Four New Stock-Billionaires

No Image 01Jun

by

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

No Image 01Jun

by

"Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

No Image 01Jun

by

G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

No Image 01Jun

by

Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money

No Image 01Jun

by

INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

No Image 01Jun

by

Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

No Image 01Jun

by

Yuhan ups investment in biotechs for immuno-oncology drug push

No Image 01Jun

by

Genosco gears up for IPO

No Image 01Jun

by

IPOs spawn instant billionaires

No Image 01Jun

by

More than half of Korean biopharma firms view R&D investments as assets.

No Image 01Jun

by

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study